Search by Drug Name or NDC
NDC 47781-0405-03 Rivastigmine Transdermal System 13.3 mg/1 Details
Rivastigmine Transdermal System 13.3 mg/1
Rivastigmine Transdermal System is a TRANSDERMAL PATCH, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Alvogen Inc.. The primary component is RIVASTIGMINE.
MedlinePlus Drug Summary
Rivastigmine transdermal patches are used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease (a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Transdermal rivastigmine is also used to treat dementia in people with Parkinson's disease (a brain system disease with symptoms of slowing of movement, muscle weakness, shuffling walk, and loss of memory). Rivastigmine is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory and thinking) by increasing the amount of a certain natural substance in the brain.
Related Packages: 47781-0405-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Rivastigmine Transdermal Patch
Product Information
| NDC | 47781-0405 |
|---|---|
| Product ID | 47781-405_ba92f242-fdc3-c9e9-71ce-0f2a7be4c1d0 |
| Associated GPIs | 62051040008540 |
| GCN Sequence Number | 069938 |
| GCN Sequence Number Description | rivastigmine PATCH TD24 13.3MG/24H TRANSDERM |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 33208 |
| HICL Sequence Number | 034884 |
| HICL Sequence Number Description | RIVASTIGMINE |
| Brand/Generic | Generic |
| Proprietary Name | Rivastigmine Transdermal System |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Rivastigmine Transdermal System |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | PATCH, EXTENDED RELEASE |
| Route | TRANSDERMAL |
| Active Ingredient Strength | 13.3 |
| Active Ingredient Units | mg/1 |
| Substance Name | RIVASTIGMINE |
| Labeler Name | Alvogen Inc. |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA204403 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 47781-0405-03 (47781040503)
| NDC Package Code | 47781-405-03 |
|---|---|
| Billing NDC | 47781040503 |
| Package | 30 POUCH in 1 CARTON (47781-405-03) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (47781-405-11) |
| Marketing Start Date | 2015-09-02 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.96723 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | RIVASTIGMINE 13.3 MG/24HR PTCH |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |